Weill Medical College of Cornell University Weill Medical College of Cornell University New York Presbyterian Hospital
Weill Medical College of Cornell University search/find News and Events
Weill Medical College of Cornell University Press Releases

NEW PRESS RELEASES

Press Releases

press archives

1998 Press Releases

Events

1997 Press Releases

Health Seminars

  


News and Events Home Page

News and Events Home Page

  

FOR IMMEDIATE RELEASE

Contact: Myrna Manners, Kathleen Robinson, Peggy Sung
Phone: (212) 821-0560
E-mail: pes2001@mail.med.cornell.edu

NON-SURGICAL TREATMENT FOR HYPERPARATHYROIDISM

Clinical Trial of a New Drug Treatment Begins at New York-Cornell

New York, NY (November 12, 1998) -- The New York Hospital-Cornell Medical Center is currently studying a drug that may offer medical treatment instead of surgery for men and women who suffer from hyperparathyroidism. To conduct this important clinical trial, the Medical Center is looking for volunteers with hyperparathyroidism to participate in a 50-day study.

Hyperparathyroidism occurs when one or more of the parathyroid glands (pea-sized glands in the neck which control the levels of calcium in the blood) produce an excess of their hormone--the parathyroid hormone. This raises the level of blood calcium above normal and weakens the bones.

Hyperparathyroidism is not uncommon among middle-aged people, and women are twice as likely to suffer from it as men. The condition usually is caused by a benign growth on one of the parathyroid glands.

The only established treatment for hyperparathyroidism is surgery. It is hoped that the clinical trial of this new drug will lead to the development of a non-surgical option for patients.

The new drug, which will be taken orally, once-a-day, is still investigational (i.e., not approved by the Food and Drug Administration). During the 50 days of the trial, participants will have a total of four days of stay in the New York Hospital-Cornell Clinical Research Center in Manhattan. They will be very carefully monitored. Study participants may receive the drug, or they may receive a placebo (no medication).

All accepted participants will receive $250 after screening and $750 after completion of the study. (Note: Parathyroid disease is totally unrelated to thyroid problems.)

Participants will continue to be treated by their own physician who will receive a full report at the end of the trail. All volunteers must be over age 18, and female volunteers must be postmenopausal for at least one year.

For more details, call David A. Zackson, M.D.
Division of Endocrinology
The New York Hospital-Cornell Medical Center
(212) 746-6290



© 1999 New York Presbyterian Hospital
Weill Medical College of Cornell University

 

Go to home page - New York Presbyterian Hospital Go to home page - Weill Medical College of Cornell University Go to home page - Weill Graduate School of Medical Sciences of Cornell University

Search Find Faculty, Students or Staff Find a Physician Search Find Faculty, Students or Staff Find a Physician